Presently, Omnipod 5 is FDA-cleared in the United States and C.E. marked for use in those with type 1 diabetes aged two years and older. The SECURE-T2D pivotal trial primarily aimed to evaluate ...

Insulet (Nasdaq:PODD) announced today that it made its Omnipod 5 automated insulin delivery system available in several new ...

The Omnipod 5 Automated Insulin Delivery System is now commercially available in Australia, launching soon in Belgium, Canada, and Switzerland. Omnipod 5 is now commercially available in Australia ...

In keeping with our new Diabetes Canada Guidelines that all people with type 1 diabetes should use an AID System, the arrival of Omnipod 5 will be life changing for many people living with ...

In August 2024, the FDA cleared Omnipod 5 for use by people with type 2 diabetes (18 years and above), expanding the technology to nearly six million insulin-requiring people in the United States.

"Canadians living with type 1 diabetes have been anxiously awaiting the arrival of Omnipod 5, the only tubeless commercial AID System. In keeping with our new Diabetes Canada Guidelines that all ...

Answer: The Omnipod system is an insulin delivery system that allows you to not only monitor your blood sugar without finger sticks, but also administer insulin without needles. This system is like an ...

PODD's shares rise on the back of its innovative Omnipod 5 system and impressive market expansion. However, the unfavorable macroeconomic scenario is concerning.

Insulet Corporation PODD announced favorable RADIANT trial clinical data for its Omnipod 5 at the 18th International Conference on Advanced Technologies and Treatments for Diabetes (“ATTD”).

“When she got the Omnipod 5, it changed everything.” Unlike traditional insulin pumps that use tubes, the Omnipod 5 adheres ...

Insulet Corporation PODD recently made its Omnipod 5 Automated Insulin Delivery (“AID”) System commercially available in Australia. Omnipod 5 is available with Dexcom G6 and G7 continuous ...